BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Bought by Boothbay Fund Management LLC

Boothbay Fund Management LLC boosted its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 16.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,384,633 shares of the biotechnology company's stock after acquiring an additional 190,574 shares during the quarter. Boothbay Fund Management LLC owned 0.67% of BioCryst Pharmaceuticals worth $10,412,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of BCRX. Venturi Wealth Management LLC bought a new stake in BioCryst Pharmaceuticals during the 4th quarter valued at $46,000. R Squared Ltd bought a new stake in BioCryst Pharmaceuticals during the 4th quarter valued at $48,000. KBC Group NV raised its position in BioCryst Pharmaceuticals by 80.1% during the 4th quarter. KBC Group NV now owns 10,198 shares of the biotechnology company's stock valued at $77,000 after purchasing an additional 4,537 shares in the last quarter. Raymond James Financial Inc. bought a new stake in BioCryst Pharmaceuticals during the 4th quarter valued at $80,000. Finally, SkyView Investment Advisors LLC raised its position in BioCryst Pharmaceuticals by 30.0% during the 3rd quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the biotechnology company's stock valued at $99,000 after purchasing an additional 3,000 shares in the last quarter. Hedge funds and other institutional investors own 85.88% of the company's stock.

BioCryst Pharmaceuticals Trading Up 0.2 %

Shares of BCRX stock traded up $0.02 during mid-day trading on Thursday, reaching $8.87. The stock had a trading volume of 1,937,807 shares, compared to its average volume of 2,820,872. The firm has a market cap of $1.85 billion, a price-to-earnings ratio of -14.53 and a beta of 1.75. BioCryst Pharmaceuticals, Inc. has a 1-year low of $4.15 and a 1-year high of $9.50. The business's fifty day moving average is $7.67 and its 200-day moving average is $7.78.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last released its quarterly earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.06). The company had revenue of $131.50 million for the quarter, compared to analysts' expectations of $126.64 million. During the same quarter in the prior year, the company earned $0.28 earnings per share. The business's revenue for the quarter was up 40.8% compared to the same quarter last year. On average, analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on BCRX shares. HC Wainwright reaffirmed a "buy" rating and set a $30.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. Wedbush assumed coverage on BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. They issued an "outperform" rating and a $15.00 price target for the company. Cantor Fitzgerald assumed coverage on BioCryst Pharmaceuticals in a research report on Tuesday. They issued an "overweight" rating and a $20.00 price target for the company. Needham & Company LLC reissued a "buy" rating and issued a $15.00 price target on shares of BioCryst Pharmaceuticals in a research report on Thursday, April 10th. Finally, Evercore ISI boosted their price target on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an "outperform" rating in a research report on Monday, January 13th. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, BioCryst Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus target price of $16.13.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.